Stockreport

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds [Yahoo! Finance]

Cadrenal Therapeutics, Inc.  (CVKD) 
PDF developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definit [Read more]